NCT00134160View on ClinicalTrials.gov

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

PHASE4CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
HypertensionCardiovascular Diseases
Interventions
DRUG

Olmesartan medoxomil

Olmesartan medoxomil 40mg/Day

DRUG

Calcium channel blockers (amlodipine, azelnidipine)

Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)

Trial Locations (2)

860-8556

Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University, 1-1-1 Honjyo, Kumamoto-City

163-1030

OSCAR-Study Data Center, ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku

All Listed Sponsors
collaborator

Japan Heart Foundation

OTHER

lead

OSCAR Study

OTHER

NCT00134160 - OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study | Biotech Hunter | Biotech Hunter